Hemodialysis patients hemodialysis, phosphate binders, MK7, menaquinone, vitaminK, dpucMGP
Conditions
Interventions
Sponsors
The College of Pharmacotherapy of Thailand
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Thai adults chronic hemodialysis patients 2.Receiving monotherapy of phosphate binder
Exclusion criteria
Exclusion criteria: 1.History of cardiovascular diseases 2.History of coagulation defects 3.History of malignancy 4.Presence of lipid absorption disorders 5.Elevated liver enzymes, above 3 times the upper limit of normal 6.Serum albumin less than 2.5 g/dL 7.Body mass index less than 18 kg/m2 8.VitaminK antagonists treatment within 90 days prior to recruitment 9.Concomitant drugs affect vitaminK levels e.g. carbamazepine, cholestyraine, lamotrigine, menadione, menaquinone, orlistat, oxcarbamazepine, phenobarbital, phenytoin, phytomenadione 10.Receiving antibiotics at least 10 days during recruitment 11.Phosphate binders dose adjustment within 30 days prior to recruitment 12.Hypersensitivity to menaquinone or any component of the formulation 13.Medication adherence less than 80% 14.Refuse to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| dp-ucMGP per-post intervantion baseline and 8 weeks after the intervention dp-ucMGP | — |
Secondary
| Measure | Time frame |
|---|---|
| dp-ucMGP between groups 8 weeks after the intervention dp-ucMGP | — |
Countries
Thailand
Contacts
Public ContactManorom Poosoonthornsri
King Chulalongkorn Memorial Hospital
Outcome results
None listed